Former Chief Financial Officer · Syndax Pharmaceuticals Inc (SNDX)

Daphne Karydas

A named executive officer of Syndax Pharmaceuticals in every fiscal year CompBrief holds from FY2020 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$2,278,520

Salary $307,670Stock awards $0Bonus $50,000

FY2020: $3,129,364

3rd of 4 named executive officers at Syndax Pharmaceuticals by FY2021 total.

4 named officers on file for Syndax Pharmaceuticals, FY2021

Daphne Karydas’s pay file — $29

  • 2 fiscal years of pay, line by line
  • SNDX’s disclosed peer group of 22 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Syndax Pharmaceuticals’s whole pay program stands against its peers

  • Syndax Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SNDX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 29, 2022 (DEF 14A).

Free

Get Daphne Karydas’s full pay file as a PDF — free

More than this page: up to 10 years of Daphne’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Daphne Karydas compensation by year

Syndax Pharmaceuticals Summary Compensation Table · all 2 fiscal years held
In US dollars, as Syndax Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021
Salary$200,881$307,670
Bonus$0$50,000
Stock awards$0$0
Option awards$2,847,733$1,782,100
Non-equity incentive$80,750$130,750
Pension and deferred compensation$0$0
All other$0$8,000
Total$3,129,364$2,278,520

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Syndax Pharmaceuticals Inc DEF 14A filed March 29, 2022, accession 0001564590-22-012198, and prior-year filings.

How this page was built: the Syndax Pharmaceuticals Inc filed document, accession 0001564590-22-012198. Every figure is read from that document and cited to the page and table it appears in. Filed March 29, 2022.

$3.1M
$2.3M
FY20
FY21
SalaryBonusNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option129,896—$18.96
Option73,229—$21.36

Per the Outstanding Equity Awards at Fiscal Year-End table in Syndax Pharmaceuticals Inc's FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Syndax Pharmaceuticals’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Briggs MorrisonChief Executive Officer$3,904,316
Michael MetzgerChief Executive Officer$3,333,905
Daphne Karydas · this pageFormer Chief Financial Officer$2,278,520
Anjali GanguliChief Business Officer$2,069,653

The full Syndax Pharmaceuticals compensation record

free company brief

This page is one person within Syndax Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Syndax Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Syndax Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Daphne Karydas's compensation dossier · One-time report. No refunds.